1. Home
  2. SNGX vs AIDX Comparison

SNGX vs AIDX Comparison

Compare SNGX & AIDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Soligenix Inc.

SNGX

Soligenix Inc.

HOLD

Current Price

$0.39

Market Cap

5.6M

Sector

Health Care

ML Signal

HOLD

Logo 20/20 Biolabs Inc. Common Stock

AIDX

20/20 Biolabs Inc. Common Stock

N/A

Current Price

$0.44

Market Cap

6.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SNGX
AIDX
Founded
1987
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Precision Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6M
6.7M
IPO Year
2006
2025

Fundamental Metrics

Financial Performance
Metric
SNGX
AIDX
Price
$0.39
$0.44
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$6.00
N/A
AVG Volume (30 Days)
245.5K
90.3K
Earning Date
05-08-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
57.03
34.48
EPS
N/A
N/A
Revenue
$119,371.00
$2,045,133.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
16.71
52 Week Low
$0.28
$0.40
52 Week High
$6.23
$14.09

Technical Indicators

Market Signals
Indicator
SNGX
AIDX
Relative Strength Index (RSI) 46.90 33.90
Support Level $0.37 $0.40
Resistance Level $0.38 $0.49
Average True Range (ATR) 0.02 0.04
MACD 0.01 0.01
Stochastic Oscillator 56.05 20.67

Price Performance

Historical Comparison
SNGX
AIDX

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).

About AIDX 20/20 Biolabs Inc. Common Stock

20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.

Share on Social Networks: